Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $75.2M (cash outflow) rose 103.0% year over year, ahead of the +52.9% change in trailing-twelve-month operating cash flow. Sequentially, it rose 43.5% from the prior quarter. Over 3 fiscal years it compounded at +37.9% a year.
Context
- Operating cash flow amounted to 1723.3% of revenue in FY2025, down 670.1 pp from a year earlier.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +103.0% holds above the trailing-twelve-month pace of +52.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (172.33M) USD
- Year-over-year change
- -44.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (172.33M) | -44.0% |
| FY2024 | 2024-12-31 | (119.67M) | -292.0% |
| FY2023 | 2023-12-31 | (30.53M) | +53.5% |
| FY2022 | 2022-12-31 | (65.65M) | — |
Operating Cash Flow vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 operating cash flow of $210.48M is the 2nd largest of the 8 companies compared; the peer median is $139.96M.
- Its year-over-year change of +52.9% is the 4th highest of 8, against a peer median of +31.0%.
- Over three fiscal years its annual growth of +37.9% compares with a peer median of +23.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $395M | -8.3% | +29.4% | 5567.4% | |
| LTM Mar 2026 | $210.48M | +52.9% | +37.9% | — | |
| LTM Mar 2026 | $183.1M | +31.0% | +17.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $142.93M | +13.6% | — | — |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $139.96M | +69.1% | +91.4% | 4213.2% |
| LTM Mar 2026 | $52.21M | +323.8% | -11.3% | 623.9% | |
| LTM Mar 2026 | $27.4M | -58.3% | +45.2% | 51.0% | |
| FY2025 | $12.85M | +953.5% | -7.0% | — | |
| Peer median (excluding ZBIO) | $139.96M | +31.0% | +23.2% | 2418.6% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.